Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-02
2010-02-02
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S729000, C514S828000, C514S844000, C424S401000
Reexamination Certificate
active
07655682
ABSTRACT:
The present invention relates to a composition comprising two or more anti-irritants, each having at least about 7.2% oxygen content. In a separate embodiment, the composition may be defined to include a skin conditioning agent, a skin protectant agent, and an anti-irritant agent, each having an oxygen content of at least about 7.2%. The invention further comprises methods of treating and preventing skin conditions by applying the composition to the skin, and then optionally washing the skin.
REFERENCES:
patent: 3634264 (1972-01-01), Pence et al.
patent: 4388301 (1983-06-01), Klein et al.
patent: 4545990 (1985-10-01), Le Foyer de Costil et al.
patent: 4587123 (1986-05-01), Price et al.
patent: 4735935 (1988-04-01), McAnalley
patent: 4752472 (1988-06-01), Kligman
patent: 4803228 (1989-02-01), Jacquet et al.
patent: 4891228 (1990-01-01), Thaman et al.
patent: 4906617 (1990-03-01), Jacquet et al.
patent: 4917891 (1990-04-01), Kaufmann et al.
patent: 4960772 (1990-10-01), Sebag et al.
patent: 5019567 (1991-05-01), Philippe et al.
patent: 5254109 (1993-10-01), Smith et al.
patent: 5368581 (1994-11-01), Smith et al.
patent: 5470884 (1995-11-01), Corless et al.
patent: 5562642 (1996-10-01), Smith et al.
patent: 5632996 (1997-05-01), Ramirez et al.
patent: 5648389 (1997-07-01), Gans et al.
patent: 5660839 (1997-08-01), Allec et al.
patent: 5690946 (1997-11-01), Koulbanis et al.
patent: 5756107 (1998-05-01), Hahn et al.
patent: 5756119 (1998-05-01), Deckner et al.
patent: 5767098 (1998-06-01), Klein et al.
patent: 5804203 (1998-09-01), Hahn et al.
patent: 5821237 (1998-10-01), Bissett et al.
patent: 5874074 (1999-02-01), Smith et al.
patent: 5874093 (1999-02-01), Eliaz et al.
patent: 5951991 (1999-09-01), Wagner et al.
patent: 5958436 (1999-09-01), Hahn et al.
patent: 5997885 (1999-12-01), Koulbanis et al.
patent: 6001380 (1999-12-01), Smith et al.
patent: 6017549 (2000-01-01), Knight et al.
patent: 6113921 (2000-09-01), Friedman et al.
patent: 6153208 (2000-11-01), McAtee et al.
patent: 6183766 (2001-02-01), Sine et al.
patent: 6338855 (2002-01-01), Albacarys et al.
patent: 6413536 (2002-07-01), Gibson et al.
patent: 6429231 (2002-08-01), Bhagwat et al.
patent: 6455076 (2002-09-01), Hahn et al.
patent: 6462025 (2002-10-01), Vishnupad
patent: 6469227 (2002-10-01), Cooke et al.
patent: 6784145 (2004-08-01), Delambre
patent: 6861397 (2005-03-01), Seitz et al.
patent: 6977081 (2005-12-01), Rood
patent: 2002/0086039 (2002-07-01), Lee et al.
patent: 2002/0164381 (2002-11-01), Shacknai et al.
patent: 2003/0031727 (2003-02-01), Hahn et al.
patent: 2005/0025817 (2005-02-01), Bhatia et al.
patent: 2005/0232978 (2005-10-01), Patel et al.
patent: 0576287 (1993-12-01), None
patent: 03-002124 (1991-01-01), None
patent: WO 82/04393 (1982-12-01), None
patent: WO 98/04241 (1998-02-01), None
patent: WO 99/24003 (1999-05-01), None
Harry, R.G., “Harry's Cosmeticology”, pp. 558-561, 6thedition (1973).
Bonnar, et al., “The Demodex Mite Population in Rosacea”, Journal of the American Academy of Dermatology, vol. 28, No. 3, pp. 443-448, Mar. 1993.
Diaz-Perez et al., “Demodex mites in Rosacea” and “Reply”, Journal of the American Academy of Dermatology, vol. 30, No. 5, Part 1, pp. 812-813, May 1994.
“Dermatology in General Medicine”, 5thedition, CD-ROM, Chapter 74, (1999).
Lin et al., “Sulfur Revisited”, Journal of the American Academy of Dermatology, vol. 18, No. 3, pp. 553-558, Mar. 1998.
Maibach, et al., “Sulfur Revisited” and “Reply”, Journal of the American Academy of Dermatology, vol. 23, No. 1, pp. 154-156, Jul. 1990.
The Merck Manual, Seventeenth Edition (1999), pp. 811-814.
Marks, “Histopathology of Rosacea”, Arch. Derm., vol. 100, pp. 683-691, Dec. 1969.
Database WPI Section Ch. Week 1986 Derwent Publications Ltd. London, GB; Class D21, AN 1986-040399 XP002245540 & RO 87 009 A (Intr Prod Cosmetice Farmec) May 30, 1985 (abstract).
Physician's Desk Reference, 2004, 58thedition, published Nov. 2003, Thomas Healthcare, pp. 1906-1907.
Merck Index pp. 697-698, 1288-1289 (1983).
Ayres et al. “Demodectic Eruptions (Demodicidosis) in the Human,” Arch. Derm., vol. 83, May 1961, pp. 816-827.
Milks, Howard Jay, “Sulfur Compounds” Practical Veterinary Pharmacology, Materia Medica and Therapeutics, 1949, Sixth Edition, pp. 552-560.
Alexander JO'D., “Hair follicle mites in men,” In Arthropods and Human Skin, Berlin: Spreinger-Verlag, 1984.
Schewach-Miller et al., “Granulomatous rosacea,” Journal of the American Academy of Dermatology, Jun. 1988, vol. 18, No. 6, pp. 1363-1362.
Dominey et al., “Papulondular demodicidosis associated with acquired immunodeficiency syndrome,” Journal of the American Academy of Dermatology, Feb. 1989, vol. 20, pp. 197-201.
Ecker, et al., “Demodex Granuloma,” Arch Dermatol; Mar. 1979, vol. 115, pp. 343-344.
Waller, T. “Aloe Vera in Personal Care Products,”Cosmetic & Toiletries, (Aug. 1992).
Moroni P., “Aloe in Cosmetic Formulations,”Cosmetic Technology(Sep. 1982).
“Aloe Vera Gel,” Handbook of Non-Prescription Drugs, American Pharmaceutical Ass'n., Washington, D.C., p. 707 (1996).
“Allantoin,” Handbook of Non-Prescription Drugs, American Pharmaceutical Ass'n., Washington, D.C., pp. 548 and 640 (1996).
Jappe, U., “Pathological Mechanisms of Acne with Special Emphasis on Propionibacterium acnes and related Therapy,”Acta Derm Venereol, ;83 pp. 241-248 (2003).
Basta-Juzbasic, A., “Demodex Folliculorum in Development of Dermatitis Rosaceiformis Steroidica and Rosacea-Related Diseases,”Clinics in Dermatology, 20 pp. 135-140 (2002).
“α-Bisabolol”Merck Index, Merck & Co., Twelve Edition, p. 208-209 (1996).
“Allantoin”Merck Index, Merck & Co., Twelve Edition, p. 48 (1996).
“Mannose”Merck Index, Merck & Co., Twelve Edition, p. 979 (1996).
Manna, S, “Determination of the Position of theO-Acetyl Group in a β-(1 →4)-Mannan (Acemannan) from Aloe barbardensis Miller,”Carbohydrate Research, 241, pp. 317-319 (1993).
CTFA Cosmetic Ingredient Handbook, pp. 64-65, 78-85 (1988).
International Cosmetic Ingredient Dictionary and Handbook, pp. 65, 69-74, 185, 2929-2938 (2002).
Steinberg, D., “U.S. Regulations Update: FDA Issues Final Monograph for Skin Protectants,”Cosmetics & Toiletries, 118(8) pp. 20-28 (Aug. 2003).
Martindale, 32d Edition, pp. 11 (1999).
Physicians' Desk Reference 57th Edition. Montvale, NJ(2003) Plexion, pp. 1926-1927.
Bhatia Kuljit S.
Gans Eugene H.
Patel Bhiku G.
Javanmard Sahar
McNichol, Jr. William J.
Medicis Pharmaceutical Corporation
Padmanabhan Sreeni
Reed Smith LLP
LandOfFree
Triple anti-irritant composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triple anti-irritant composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triple anti-irritant composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175842